Advanced Oncotherapy PLC
LSE:AVO
Advanced Oncotherapy PLC
LSE:AVO
Price:
1.925
GBX
Market Closed
Market Cap:
£9.1m
Balance Sheet
Balance Sheet Decomposition
Advanced Oncotherapy PLC
Advanced Oncotherapy PLC
Balance Sheet Decomposition is not available for
Advanced Oncotherapy PLC
Advanced Oncotherapy PLC
Balance Sheet
Advanced Oncotherapy PLC
Advanced Oncotherapy PLC
Currency: GBP
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
0
|
0
|
1
|
9
|
1
|
0
|
1
|
3
|
2
|
4
|
|
| Cash Equivalents |
0
|
0
|
1
|
9
|
1
|
0
|
1
|
3
|
2
|
4
|
|
| Total Receivables |
1
|
1
|
0
|
3
|
3
|
4
|
1
|
2
|
1
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
1
|
1
|
0
|
3
|
3
|
4
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
1
|
4
|
7
|
8
|
10
|
15
|
22
|
26
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
1
|
0
|
|
| Total Current Assets |
2
|
1
|
3
|
17
|
13
|
13
|
14
|
22
|
26
|
31
|
|
| PP&E Net |
0
|
1
|
1
|
1
|
1
|
1
|
4
|
39
|
38
|
41
|
|
| PP&E Gross |
0
|
1
|
1
|
1
|
1
|
1
|
4
|
39
|
38
|
41
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
3
|
4
|
5
|
|
| Intangible Assets |
0
|
7
|
9
|
13
|
23
|
31
|
40
|
49
|
57
|
69
|
|
| Note Receivable |
1
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
|
| Long-Term Investments |
3
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
6
N/A
|
11
+91%
|
14
+35%
|
31
+112%
|
38
+23%
|
45
+21%
|
59
+31%
|
111
+86%
|
122
+10%
|
141
+16%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
1
|
1
|
1
|
0
|
2
|
4
|
3
|
2
|
2
|
2
|
|
| Accrued Liabilities |
1
|
1
|
1
|
2
|
1
|
3
|
3
|
3
|
5
|
3
|
|
| Short-Term Debt |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
3
|
3
|
1
|
1
|
1
|
9
|
3
|
2
|
13
|
11
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
6
|
5
|
3
|
3
|
4
|
17
|
9
|
6
|
19
|
16
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
45
|
38
|
43
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
17
|
17
|
21
|
21
|
|
| Total Liabilities |
6
N/A
|
5
-7%
|
3
-38%
|
3
+4%
|
4
+6%
|
17
+355%
|
25
+52%
|
68
+167%
|
78
+15%
|
80
+2%
|
|
| Equity | |||||||||||
| Common Stock |
3
|
6
|
10
|
14
|
18
|
20
|
42
|
61
|
83
|
113
|
|
| Retained Earnings |
5
|
7
|
14
|
20
|
29
|
41
|
61
|
80
|
104
|
125
|
|
| Additional Paid In Capital |
2
|
7
|
15
|
33
|
43
|
43
|
51
|
60
|
61
|
71
|
|
| Other Equity |
0
|
0
|
0
|
0
|
2
|
6
|
1
|
1
|
3
|
2
|
|
| Total Equity |
0
N/A
|
5
N/A
|
11
+107%
|
27
+145%
|
34
+25%
|
29
-16%
|
34
+19%
|
43
+26%
|
44
+3%
|
61
+39%
|
|
| Total Liabilities & Equity |
6
N/A
|
11
+91%
|
14
+35%
|
31
+112%
|
38
+23%
|
45
+21%
|
59
+31%
|
111
+86%
|
122
+10%
|
141
+16%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
10
|
24
|
41
|
57
|
72
|
81
|
170
|
244
|
333
|
452
|
|
Switch to:
Switch to:
See Also
Discover More
